Who makes [13C2,15N3]-tebapivat?

[13C2,15N3]-tebapivat is developed by Agios Pharmaceuticals, Inc..

What development phase is [13C2,15N3]-tebapivat in?

[13C2,15N3]-tebapivat is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[13C2,15N3]-tebapivat

Agios Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	[13C2,15N3]-tebapivat
Sponsor	Agios Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[13C2,15N3]-tebapivat CI brief — competitive landscape report
[13C2,15N3]-tebapivat updates RSS · CI watch RSS
Agios Pharmaceuticals, Inc. portfolio CI